{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:13:58Z","timestamp":1790475238076,"version":"4.1.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12013-023-01164-x","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:02:19Z","timestamp":1693594939000},"page":"599-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-5619","authenticated-orcid":false,"given":"Amirhossein","family":"Niknejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-5555","authenticated-orcid":false,"given":"Yasamin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-033X","authenticated-orcid":false,"given":"Hedieh Sadat","family":"Shamsnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-3011","authenticated-orcid":false,"given":"Ayeh Sabbagh","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-9514","authenticated-orcid":false,"given":"Fatemeh","family":"Rostamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3957-3300","authenticated-orcid":false,"given":"Saeideh","family":"Momtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-9097","authenticated-orcid":false,"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"6","key":"1164_CR1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrendo.2016.53","volume":"12","author":"R Unnikrishnan","year":"2016","unstructured":"Unnikrishnan, R., Anjana, R. M., & Mohan, V. (2016). Diabetes mellitus and its complications in India. Nature Reviews Endocrinology, 12(6), 357\u2013370.","journal-title":"Nature Reviews Endocrinology"},{"issue":"5","key":"1164_CR2","doi-asserted-by":"crossref","first-page":"e033231","DOI":"10.1136\/bmjopen-2019-033231","volume":"10","author":"M Stedman","year":"2020","unstructured":"Stedman, M., et al. (2020). Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation. BMJ Open, 10(5), e033231.","journal-title":"BMJ Open"},{"issue":"7","key":"1164_CR3","doi-asserted-by":"crossref","first-page":"e14570","DOI":"10.1111\/dme.14570","volume":"38","author":"L Reid","year":"2021","unstructured":"Reid, L., Baxter, F., & Forbes, S. (2021). Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes. Diabetic Medicine, 38(7), e14570.","journal-title":"Diabetic Medicine"},{"key":"1164_CR4","doi-asserted-by":"crossref","unstructured":"Azhar, A., et al. (2023). Prevalence of peripheral arterial disease in diabetic foot ulcer patients and its impact in limb salvage. The International Journal of Lower Extremity Wounds, 22, 518\u2013523.","DOI":"10.1177\/15347346211027063"},{"issue":"2","key":"1164_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/diaclin.26.2.77","volume":"26","author":"MJ Fowler","year":"2008","unstructured":"Fowler, M. J. (2008). Microvascular and macrovascular complications of diabetes. Clinical diabetes, 26(2), 77\u201382.","journal-title":"Clinical diabetes"},{"issue":"3","key":"1164_CR6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2337\/diaclin.29.3.116","volume":"29","author":"MJ Fowler","year":"2011","unstructured":"Fowler, M. J. (2011). Microvascular and macrovascular complications of diabetes. Clinical diabetes, 29(3), 116\u2013122.","journal-title":"Clinical diabetes"},{"issue":"6","key":"1164_CR7","first-page":"809","volume":"70","author":"K Luc","year":"2019","unstructured":"Luc, K. et al. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. J of Physiology and Pharmacology, 70(6), 809\u2013824.","journal-title":"J of Physiology and Pharmacology"},{"issue":"4","key":"1164_CR8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","volume":"143","author":"F Zannad","year":"2021","unstructured":"Zannad, F., et al. (2021). Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced. Circulation, 143(4), 310\u2013321.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1164_CR9","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc23-Srev","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed, N. A., et al. (2023). Summary of revisions: standards of care in diabetes-2023. Diabetes Care, 46(Suppl 1), S5\u2013s9.","journal-title":"Diabetes Care"},{"issue":"3","key":"1164_CR10","first-page":"294","volume":"20","author":"B Saberzadeh-Ardestani","year":"2018","unstructured":"Saberzadeh-Ardestani, B., et al. (2018). Type 1 diabetes mellitus: cellular and molecular pathophysiology at a glance. Cell Journal, 20(3), 294.","journal-title":"Cell Journal"},{"key":"1164_CR11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fendo.2020.00248","volume":"11","author":"M Primavera","year":"2020","unstructured":"Primavera, M., Giannini, C., & Chiarelli, F. (2020). Prediction and prevention of type 1 diabetes. Frontiers in Endocrinology, 11, 248.","journal-title":"Frontiers in Endocrinology"},{"issue":"4","key":"1164_CR12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/biology11040608","volume":"11","author":"K Zorena","year":"2022","unstructured":"Zorena, K., et al. (2022). Environmental factors and the risk of developing type 1 diabetes\u2014old disease and new data. Biology, 11(4), 608.","journal-title":"Biology"},{"issue":"2","key":"1164_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/mca25020023","volume":"25","author":"D Gamboa","year":"2020","unstructured":"Gamboa, D., V\u00e1zquez, C. E., & Campos, P. J. (2020). Nonlinear analysis for a type-1 diabetes model with focus on t-cells and pancreatic \u03b2-cells behavior. Mathematical and Computational Applications, 25(2), 23.","journal-title":"Mathematical and Computational Applications"},{"issue":"2","key":"1164_CR14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2249.2008.03860.x","volume":"155","author":"A Willcox","year":"2009","unstructured":"Willcox, A., et al. (2009). Analysis of islet inflammation in human type 1 diabetes. Clinical & Experimental Immunology, 155(2), 173\u2013181.","journal-title":"Clinical & Experimental Immunology"},{"issue":"7892","key":"1164_CR15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(74)90140-8","volume":"304","author":"G Bottazzo","year":"1974","unstructured":"Bottazzo, G., Florin-Christensen, A., & Doniach, D. (1974). Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. The Lancet, 304(7892), 1279\u20131283.","journal-title":"The Lancet"},{"key":"1164_CR16","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"D Nathan","year":"2005","unstructured":"Nathan, D. (2005). for the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine, 353, 2643\u20132653.","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"1164_CR17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1055\/s-2006-954586","volume":"38","author":"A Picardi","year":"2006","unstructured":"Picardi, A., et al. (2006). Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Hormone and Metabolic Research, 38(10), 668\u2013672.","journal-title":"Hormone and Metabolic Research"},{"issue":"7","key":"1164_CR18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41590-018-0130-2","volume":"19","author":"EF Verdu","year":"2018","unstructured":"Verdu, E. F., & Danska, J. S. (2018). Common ground: shared risk factors for type 1 diabetes and celiac disease. Nature Immunology, 19(7), 685\u2013695.","journal-title":"Nature Immunology"},{"issue":"1","key":"1164_CR19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.30699\/fhi.v10i1.286","volume":"10","author":"NM Yazdani","year":"2021","unstructured":"Yazdani, N. M., & Moghaddam, R. K. (2021). Blood glucose regulation in patients with type 1 diabetes by robust optimal safety critical control. Frontiers in Health Informatics, 10(1), 80.","journal-title":"Frontiers in Health Informatics"},{"issue":"8","key":"1164_CR20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-8587(22)00141-3","volume":"10","author":"M Ghalwash","year":"2022","unstructured":"Ghalwash, M., et al. (2022). Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. The Lancet Diabetes & Endocrinology, 10(8), 589\u2013596.","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"3","key":"1164_CR21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-018-4763-3","volume":"62","author":"CC Patterson","year":"2019","unstructured":"Patterson, C. C., et al. (2019). Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989\u20132013: a multicentre prospective registration study. Diabetologia, 62(3), 408\u2013417.","journal-title":"Diabetologia"},{"key":"1164_CR22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diabres.2018.11.005","volume":"149","author":"C Piffaretti","year":"2019","unstructured":"Piffaretti, C., et al. (2019). Trends in childhood type 1 diabetes incidence in France, 2010\u20132015. Diabetes Research and Clinical Practice, 149, 200\u2013207.","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"10138","key":"1164_CR23","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Type 1 diabetes. The Lancet, 391(10138), 2449\u20132462.","journal-title":"The Lancet"},{"issue":"1","key":"1164_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-019-0484-y","volume":"20","author":"I Kyrou","year":"2020","unstructured":"Kyrou, I., et al. (2020). Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: a narrative review with emphasis on data from Europe. BMC endocrine disorders, 20(1), 1\u201313.","journal-title":"BMC endocrine disorders"},{"issue":"3","key":"1164_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/joim.13082","volume":"288","author":"H Yaghootkar","year":"2020","unstructured":"Yaghootkar, H., et al. (2020). Ethnic differences in adiposity and diabetes risk\u2013insights from genetic studies. Journal of Internal Medicine, 288(3), 271\u2013283.","journal-title":"Journal of Internal Medicine"},{"key":"1164_CR26","doi-asserted-by":"crossref","first-page":"175394472097771","DOI":"10.1177\/1753944720977715","volume":"14","author":"VM Mart\u00edn Gim\u00e9nez","year":"2020","unstructured":"Mart\u00edn Gim\u00e9nez, V. M., et al. (2020). Differences in RAAS\/vitamin D linked to genetics and socioeconomic factors could explain the higher mortality rate in African Americans with COVID-19. Therapeutic Advances in Cardiovascular Disease, 14, 1753944720977715.","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"6","key":"1164_CR27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/1389202920666191009110724","volume":"20","author":"FZ Kadayifci","year":"2019","unstructured":"Kadayifci, F. Z., et al. (2019). Early-life programming of type 2 diabetes mellitus: understanding the association between epigenetics\/genetics and environmental factors. Current Genomics, 20(6), 453\u2013463.","journal-title":"Current Genomics"},{"issue":"7","key":"1164_CR28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4239\/wjd.v13.i7.482","volume":"13","author":"SN Seneviratne","year":"2022","unstructured":"Seneviratne, S. N., & Rajindrajith, S. (2022). Fetal programming of obesity and type 2 diabetes. World Journal of Diabetes, 13(7), 482\u2013497.","journal-title":"World Journal of Diabetes"},{"issue":"11","key":"1164_CR29","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1097\/HJH.0000000000002156","volume":"37","author":"M Tian","year":"2019","unstructured":"Tian, M., et al. (2019). Low birth weight, a risk factor for diseases in later life, is a surrogate of insulin resistance at birth. Journal of hypertension, 37(11), 2123\u20132134.","journal-title":"Journal of hypertension"},{"key":"1164_CR30","doi-asserted-by":"crossref","first-page":"112578","DOI":"10.1016\/j.physbeh.2019.112578","volume":"208","author":"MC Farruggia","year":"2019","unstructured":"Farruggia, M. C., & Small, D. M. (2019). Effects of adiposity and metabolic dysfunction on cognition: a review. Physiology & Behavior, 208, 112578.","journal-title":"Physiology & Behavior"},{"key":"1164_CR31","doi-asserted-by":"crossref","first-page":"110744","DOI":"10.1016\/j.nut.2020.110744","volume":"74","author":"AR Matsuo","year":"2020","unstructured":"Matsuo, A. R., et al. (2020). Tri-ponderal mass index as a tool for insulin resistance prediction in overweight adolescents: a cross-sectional study. Nutrition, 74, 110744.","journal-title":"Nutrition"},{"issue":"19","key":"1164_CR32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM198805123181901","volume":"318","author":"S Lillioja","year":"1988","unstructured":"Lillioja, S., et al. (1988). Impaired glucose tolerance as a disorder of insulin action. New England Journal of Medicine, 318(19), 1217\u20131225.","journal-title":"New England Journal of Medicine"},{"issue":"8651","key":"1164_CR33","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(89)92804-3","volume":"333","author":"M Saad","year":"1989","unstructured":"Saad, M., et al. (1989). Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. The Lancet, 333(8651), 1356\u20131359.","journal-title":"The Lancet"},{"issue":"10","key":"1164_CR34","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0026-0495(90)90168-C","volume":"39","author":"D Jallut","year":"1990","unstructured":"Jallut, D., et al. (1990). Impaired glucose tolerance and diabetes in obesity: A 6-year follow-up study of glucose metabolism. Metabolism, 39(10), 1068\u20131075.","journal-title":"Metabolism"},{"issue":"5","key":"1164_CR35","first-page":"Cr186","volume":"9","author":"M Straczkowski","year":"2003","unstructured":"Straczkowski, M., et al. (2003). Insulin resistance in the first-degree relatives of persons with type 2 diabetes. Medical Science Monitor, 9(5), Cr186\u2013Cr190.","journal-title":"Medical Science Monitor"},{"issue":"4","key":"1164_CR36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pcad.2019.08.004","volume":"62","author":"S Carbone","year":"2019","unstructured":"Carbone, S., et al. (2019). Obesity, risk of diabetes and role of physical activity, exercise training and cardiorespiratory fitness. Progress in Cardiovascular Diseases, 62(4), 327\u2013333.","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"11","key":"1164_CR37","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2174\/1567205016666191106094356","volume":"16","author":"E Moyse","year":"2019","unstructured":"Moyse, E., et al. (2019). Common pathological mechanisms and risk factors for Alzheimer\u2019s disease and type-2 diabetes: focus on inflammation. Current Alzheimer Research, 16(11), 986\u20131006.","journal-title":"Current Alzheimer Research"},{"key":"1164_CR38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jnutbio.2018.10.003","volume":"63","author":"S Sharma","year":"2019","unstructured":"Sharma, S., & Tripathi, P. (2019). Gut microbiome and type 2 diabetes: where we are and where to go?. Journal of Nutritional Biochemistry, 63, 101\u2013108.","journal-title":"Journal of Nutritional Biochemistry"},{"issue":"6","key":"1164_CR39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dme.13609","volume":"35","author":"T Candler","year":"2018","unstructured":"Candler, T., et al. (2018). Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabetic Medicine, 35(6), 737\u2013744.","journal-title":"Diabetic Medicine"},{"key":"1164_CR40","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H., et al. (2022). IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice, 183, 109119.","journal-title":"Diabetes Research and Clinical Practice"},{"key":"1164_CR41","doi-asserted-by":"crossref","unstructured":"Bekele, H., et al. (2020). Barriers and strategies to lifestyle and dietary pattern interventions for prevention and management of type-2 diabetes in Africa, systematic review. Journal of Diabetes Research, 2020, 7948712.","DOI":"10.1155\/2020\/7948712"},{"issue":"12","key":"1164_CR42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4239\/wjd.v9.i12.209","volume":"9","author":"K Blaslov","year":"2018","unstructured":"Blaslov, K., et al. (2018). Treatment approach to type 2 diabetes: past, present and future. World Journal of Diabetes, 9(12), 209.","journal-title":"World Journal of Diabetes"},{"issue":"6","key":"1164_CR43","doi-asserted-by":"crossref","first-page":"e3158","DOI":"10.1002\/dmrr.3158","volume":"35","author":"W Jia","year":"2019","unstructured":"Jia, W., et al. (2019). Standards of medical care for type 2 diabetes in China 2019. Diabetes\/Metabolism Research and Reviews, 35(6), e3158.","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"issue":"3","key":"1164_CR44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/156652409787847137","volume":"9","author":"M Li","year":"2009","unstructured":"Li, M., et al. (2009). The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Current Molecular Medicine, 9(3), 365\u2013374.","journal-title":"Current Molecular Medicine"},{"issue":"2","key":"1164_CR45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12016-019-08742-z","volume":"58","author":"MI Arleevskaya","year":"2020","unstructured":"Arleevskaya, M. I., et al. (2020). Toll-like receptors, infections, and rheumatoid arthritis. Clinical Reviews in Allergy & Immunology, 58(2), 172\u2013181.","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"5","key":"1164_CR46","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaci.2006.02.023","volume":"117","author":"T Kaisho","year":"2006","unstructured":"Kaisho, T., & Akira, S. (2006). Toll-like receptor function and signaling. Journal of Allergy and Clinical Immunology, 117(5), 979\u2013987.","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"1164_CR47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.icb.7100100","volume":"85","author":"AJ Thompson","year":"2007","unstructured":"Thompson, A. J., & Locarnini, S. A. (2007). Toll\u2010like receptors, RIG\u2010I\u2010like RNA helicases and the antiviral innate immune response. Immunology and Cell Biology, 85(6), 435\u2013445.","journal-title":"Immunology and Cell Biology"},{"issue":"9","key":"1164_CR48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2443.2001.00458.x","volume":"6","author":"K Takeda","year":"2001","unstructured":"Takeda, K., & Akira, S. (2001). Roles of Toll\u2010like receptors in innate immune responses. Genes to Cells, 6(9), 733\u2013742.","journal-title":"Genes to Cells"},{"issue":"4","key":"1164_CR49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jlb.67.4.450","volume":"67","author":"M Muzio","year":"2000","unstructured":"Muzio, M., et al. (2000). Toll\u2010like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. Journal of Leukocyte Biology, 67(4), 450\u2013456.","journal-title":"Journal of Leukocyte Biology"},{"issue":"2","key":"1164_CR50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(02)00228-6","volume":"85","author":"S Akira","year":"2003","unstructured":"Akira, S., & Hemmi, H. (2003). Recognition of pathogen-associated molecular patterns by TLR family. Immunology Letters, 85(2), 85\u201395.","journal-title":"Immunology Letters"},{"issue":"7","key":"1164_CR51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S Akira","year":"2004","unstructured":"Akira, S., & Takeda, K. (2004). Toll-like receptor signalling. Nature Reviews Immunology, 4(7), 499\u2013511.","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"1164_CR52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.22306","volume":"48","author":"E Seki","year":"2008","unstructured":"Seki, E., & Brenner, D. A. (2008). Toll\u2010like receptors and adaptor molecules in liver disease: update. Hepatology, 48(1), 322\u2013335.","journal-title":"Hepatology"},{"key":"1164_CR53","doi-asserted-by":"crossref","first-page":"784484","DOI":"10.3389\/fimmu.2021.784484","volume":"12","author":"S Nimma","year":"2021","unstructured":"Nimma, S., et al. (2021). Structural evolution of TIR-domain signalosomes. Frontiers in Immunology, 12, 784484.","journal-title":"Frontiers in Immunology"},{"issue":"5633","key":"1164_CR54","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","volume":"301","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto, M., et al. (2003). Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 301(5633), 640\u2013643.","journal-title":"Science"},{"issue":"5","key":"1164_CR55","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.173.5.2913","volume":"173","author":"J Gohda","year":"2004","unstructured":"Gohda, J., Matsumura, T., & Inoue, J.-I. (2004). Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not Toll\/IL-1 receptor domain-containing adaptor-inducing IFN-\u03b2 (TRIF)-dependent pathway in TLR signaling. The Journal of Immunology, 173(5), 2913\u20132917.","journal-title":"The Journal of Immunology"},{"issue":"4","key":"1164_CR56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1753425913498626","volume":"20","author":"ST Kolanowski","year":"2014","unstructured":"Kolanowski, S. T., et al. (2014). TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF. Innate Immunity, 20(4), 423\u2013430.","journal-title":"Innate Immunity"},{"issue":"5","key":"1164_CR57","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1038\/cddis.2016.140","volume":"7","author":"Y Yang","year":"2016","unstructured":"Yang, Y., et al. (2016). The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death & Disease, 7(5), e2234\u2013e2234.","journal-title":"Cell Death & Disease"},{"key":"1164_CR58","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fimmu.2018.00867","volume":"9","author":"X Zhao","year":"2018","unstructured":"Zhao, X., et al. (2018). IRF3 negatively regulates toll-like receptor-mediated NF-\u03baB signaling by targeting TRIF for degradation in teleost fish. Frontiers in Immunology, 9, 867.","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"1164_CR59","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald, K. A., & Kagan, J. C. (2020). Toll-like receptors and the control of immunity. Cell, 180(6), 1044\u20131066.","journal-title":"Cell"},{"issue":"8","key":"1164_CR60","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/138920312804871148","volume":"13","author":"O Fekonja","year":"2012","unstructured":"Fekonja, O., Avbelj, M., & Jerala, R. (2012). Suppression of TLR signaling by targeting TIR domain-containing proteins. Current Protein and Peptide Science, 13(8), 776\u2013788.","journal-title":"Current Protein and Peptide Science"},{"key":"1164_CR61","doi-asserted-by":"crossref","unstructured":"Cole, J. E., Georgiou, E. & Monaco, C. (2010). The expression and functions of toll-like receptors in atherosclerosis. Mediators of inflammation, 2010, ID 393946.","DOI":"10.1155\/2010\/393946"},{"issue":"14","key":"1164_CR62","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00018-020-03453-7","volume":"77","author":"B Li","year":"2020","unstructured":"Li, B., Xia, Y., & Hu, B. (2020). Infection and atherosclerosis: TLR-dependent pathways. Cellular and Molecular Life Sciences, 77(14), 2751\u20132769.","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"3","key":"1164_CR63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13813455.2011.562514","volume":"117","author":"M Fresno","year":"2011","unstructured":"Fresno, M., Alvarez, R., & Cuesta, N. (2011). Toll-like receptors, inflammation, metabolism and obesity. Archives of Physiology and Biochemistry, 117(3), 151\u2013164.","journal-title":"Archives of Physiology and Biochemistry"},{"issue":"2","key":"1164_CR64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2021","unstructured":"Fillatreau, S., Manfroi, B., & D\u00f6rner, T. (2021). Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nature Reviews Rheumatology, 17(2), 98\u2013108.","journal-title":"Nature Reviews Rheumatology"},{"key":"1164_CR65","doi-asserted-by":"crossref","unstructured":"Spirig, R., Tsui, J. & Shaw, S. (2012). The emerging role of TLR and innate immunity in cardiovascular disease. Cardiology Research and Practice, 2012, 181394.","DOI":"10.1155\/2012\/181394"},{"key":"1164_CR66","doi-asserted-by":"crossref","unstructured":"Chedid, P., Salami, A. & El Shamieh, S. (2020). The association of rs1898830 in toll-like receptor 2 with lipids and blood pressure. Journal of Cardiovascular Development and Disease, 7(3) 24.","DOI":"10.3390\/jcdd7030024"},{"key":"1164_CR67","doi-asserted-by":"crossref","unstructured":"Ashayeri Ahmadabad, R., et al. (2021). Toll-like receptor signaling pathways: novel therapeutic targets for cerebrovascular disorders. International Journal of Molecular Science, 22(11), 6153.","DOI":"10.3390\/ijms22116153"},{"issue":"Pt B","key":"1164_CR68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.neuropharm.2018.07.022","volume":"145","author":"H Shi","year":"2019","unstructured":"Shi, H., et al. (2019). Role of Toll-like receptor mediated signaling in traumatic brain injury. Neuropharmacology, 145(Pt B), 259\u2013267.","journal-title":"Neuropharmacology"},{"issue":"10","key":"1164_CR69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14728222.2019.1676416","volume":"23","author":"GR Leitner","year":"2019","unstructured":"Leitner, G. R., et al. (2019). Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. Expert Opinion on Therapeutic Targets, 23(10), 865\u2013882.","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"1164_CR70","doi-asserted-by":"crossref","unstructured":"Momtaz, S., et al. (2023). The Hydro-alcoholic Extract of Achillea wilhelmsii C. Koch Ameliorates Acetic Acid-induced Ulcerative Colitis through TLR-4. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences, 93, 127\u2013135.","DOI":"10.1007\/s40011-022-01404-9"},{"issue":"3","key":"1164_CR71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","volume":"13","author":"E Lontchi-Yimagou","year":"2013","unstructured":"Lontchi-Yimagou, E., et al. (2013). Diabetes mellitus and inflammation. Current Diabetes Reports, 13(3), 435\u2013444.","journal-title":"Current Diabetes Reports"},{"key":"1164_CR72","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1902\/jop.2008.080246","volume":"79","author":"GL King","year":"2008","unstructured":"King, G. L. (2008). The role of inflammatory cytokines in diabetes and its complications. Journal of Periodontology, 79, 1527\u20131534.","journal-title":"Journal of Periodontology"},{"issue":"4","key":"1164_CR73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2009.21","volume":"5","author":"DL Eizirik","year":"2009","unstructured":"Eizirik, D. L., Colli, M. L., & Ortis, F. (2009). The role of inflammation in insulitis and \u03b2-cell loss in type 1 diabetes. Nature Reviews Endocrinology, 5(4), 219\u2013226.","journal-title":"Nature Reviews Endocrinology"},{"issue":"11","key":"1164_CR74","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41574-020-00409-6","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik, D. L., & Colli, M. L. (2020). Revisiting the role of inflammation in the loss of pancreatic \u03b2-cells in T1DM. Nature Reviews Endocrinology, 16(11), 611\u2013612.","journal-title":"Nature Reviews Endocrinology"},{"issue":"4","key":"1164_CR75","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.immuni.2009.08.023","volume":"31","author":"M Feuerer","year":"2009","unstructured":"Feuerer, M., et al. (2009). How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity, 31(4), 654\u2013664.","journal-title":"Immunity"},{"issue":"3","key":"1164_CR76","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","volume":"52","author":"J Spranger","year":"2003","unstructured":"Spranger, J., et al. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes, 52(3), 812\u2013817.","journal-title":"Diabetes"},{"issue":"3","key":"1164_CR77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan, A. D., et al. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286(3), 327\u2013334.","journal-title":"JAMA"},{"issue":"3","key":"1164_CR78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2119\/2007-00119.Tilg","volume":"14","author":"H Tilg","year":"2008","unstructured":"Tilg, H., & Moschen, A. R. (2008). Inflammatory mechanisms in the regulation of insulin resistance. Molecular Medicine, 14(3), 222\u2013231.","journal-title":"Molecular Medicine"},{"issue":"4","key":"1164_CR79","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/icb.2014.4","volume":"92","author":"C Westwell\u2010Roper","year":"2014","unstructured":"Westwell\u2010Roper, C., et al. (2014). Toll\u2010like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunology and Cell Biology, 92(4), 314\u2013323.","journal-title":"Immunology and Cell Biology"},{"issue":"11","key":"1164_CR80","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.4049\/jimmunol.0901517","volume":"183","author":"M Jagannathan","year":"2009","unstructured":"Jagannathan, M., et al. (2009). TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. The Journal of Immunology, 183(11), 7461\u20137470.","journal-title":"The Journal of Immunology"},{"issue":"1","key":"1164_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"S Gupta","year":"2017","unstructured":"Gupta, S., et al. (2017). Analysis of inflammatory cytokine and TLR expression levels in Type 2 Diabetes with complications. Scientific Reports, 7(1), 1\u201310.","journal-title":"Scientific Reports"},{"issue":"4","key":"1164_CR82","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2337\/dc09-1799","volume":"33","author":"MR Dasu","year":"2010","unstructured":"Dasu, M. R., et al. (2010). Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care, 33(4), 861\u2013868.","journal-title":"Diabetes Care"},{"issue":"2","key":"1164_CR83","doi-asserted-by":"crossref","first-page":"F143","DOI":"10.1152\/ajprenal.00398.2012","volume":"305","author":"H Mudaliar","year":"2013","unstructured":"Mudaliar, H., et al. (2013). The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. American Journal of Physiology-Renal Physiology, 305(2), F143\u2013F154.","journal-title":"American Journal of Physiology-Renal Physiology"},{"issue":"2","key":"1164_CR84","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2007-2185","volume":"93","author":"S Devaraj","year":"2008","unstructured":"Devaraj, S., et al. (2008). Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. The Journal of Clinical Endocrinology & Metabolism, 93(2), 578\u2013583.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"7","key":"1164_CR85","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-010-1730-z","volume":"53","author":"M Jagannathan","year":"2010","unstructured":"Jagannathan, M., et al. (2010). Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia, 53(7), 1461\u20131471.","journal-title":"Diabetologia"},{"issue":"4","key":"1164_CR86","first-page":"559","volume":"20","author":"ZE Karaali","year":"2019","unstructured":"Karaali, Z. E., et al. (2019). Toll-like receptor 2 (TLR-2) gene polymorphisms in type 2 diabetes mellitus. Cell Journal, 20(4), 559.","journal-title":"Cell Journal"},{"issue":"1","key":"1164_CR87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nut.2014.04.019","volume":"31","author":"M Andrews","year":"2015","unstructured":"Andrews, M., Soto, N., & Arredondo-Olgu\u00edn, M. (2015). Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity. Nutrition, 31(1), 51\u201357.","journal-title":"Nutrition"},{"issue":"3","key":"1164_CR88","doi-asserted-by":"crossref","first-page":"e12324","DOI":"10.1111\/cpr.12324","volume":"50","author":"G Chen","year":"2017","unstructured":"Chen, G., et al. (2017). Maternal diabetes modulates offspring cell proliferation and apoptosis during odontogenesis via the TLR 4\/NF\u2010\u03baB signalling pathway. Cell Proliferation, 50(3), e12324.","journal-title":"Cell Proliferation"},{"issue":"3","key":"1164_CR89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cyto.2011.03.023","volume":"55","author":"S Devaraj","year":"2011","unstructured":"Devaraj, S., Tobias, P., & Jialal, I. (2011). Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine, 55(3), 441\u2013445.","journal-title":"Cytokine"},{"issue":"1","key":"1164_CR90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1681\/ASN.2010111210","volume":"23","author":"M Lin","year":"2012","unstructured":"Lin, M., et al. (2012). Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. Journal of the American Society of Nephrology, 23(1), 86\u2013102.","journal-title":"Journal of the American Society of Nephrology"},{"key":"1164_CR91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2018.01.003","volume":"822","author":"Y Yamazaki","year":"2018","unstructured":"Yamazaki, Y., Harada, S., & Tokuyama, S. (2018). Sodium-glucose transporter as a novel therapeutic target in disease. Europeon Journal of Pharmacology, 822, 25\u201331.","journal-title":"Europeon Journal of Pharmacology"},{"issue":"9","key":"1164_CR92","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00424-020-02433-x","volume":"472","author":"G Gyimesi","year":"2020","unstructured":"Gyimesi, G., et al. (2020). Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Archiv, 472(9), 1177\u20131206.","journal-title":"Pflugers Archiv"},{"issue":"2","key":"1164_CR93","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright, E. M., Loo, D. D., & Hirayama, B. A. (2011). Biology of human sodium glucose transporters. Physiological Reviews, 91(2), 733\u2013794.","journal-title":"Physiological Reviews"},{"issue":"10","key":"1164_CR94","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"C Ghezzi","year":"2018","unstructured":"Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018). Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia, 61(10), 2087\u20132097.","journal-title":"Diabetologia"},{"key":"1164_CR95","doi-asserted-by":"crossref","unstructured":"Hou, Y. C., et al. (2020). Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Internaltional Journal of Molecular Science, 21(21) 7833.","DOI":"10.3390\/ijms21217833"},{"key":"1164_CR96","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon, V., & Verma, S. (2021). Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annual Review of Physiology, 83, 503\u2013528.","journal-title":"Annual Review of Physiology"},{"issue":"1","key":"1164_CR97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano, D., et al. (2021). Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 20(1), 17.","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"1164_CR98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","volume":"21","author":"Y Suzuki","year":"2022","unstructured":"Suzuki, Y., et al. (2022). Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovascular Diabetology, 21(1), 67.","journal-title":"Cardiovascular Diabetology"},{"key":"1164_CR99","doi-asserted-by":"crossref","unstructured":"Dago, M., et al. (2022). Empagliflozin and dapagliflozin increase Na(+) and inward rectifier K(+) current densities in human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CMs). Cells, 11(23), 3707.","DOI":"10.3390\/cells11233707"},{"key":"1164_CR100","doi-asserted-by":"crossref","unstructured":"Waugh, D. T. (2019). Fluoride exposure induces inhibition of sodium-and potassium-activated adenosine triphosphatase (Na(+), K(+)-ATPase) enzyme activity: molecular mechanisms and implications for public health. International Journal of Environmental Research and Public Health, 16(8), 1427.","DOI":"10.3390\/ijerph16081427"},{"issue":"8","key":"1164_CR101","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00018-012-1134-y","volume":"70","author":"W Fuller","year":"2013","unstructured":"Fuller, W., et al. (2013). Regulation of the cardiac sodium pump. Cellular and Molecular Life Sciences, 70(8), 1357\u20131380.","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"4","key":"1164_CR102","doi-asserted-by":"crossref","first-page":"e00505","DOI":"10.1002\/prp2.505","volume":"7","author":"A Askari","year":"2019","unstructured":"Askari, A. (2019). The sodium pump and digitalis drugs: Dogmas and fallacies. Pharmacology Research and Perspectives, 7(4), e00505.","journal-title":"Pharmacology Research and Perspectives"},{"key":"1164_CR103","doi-asserted-by":"publisher","unstructured":"Kowalska, K., et al. (2021) Empagliflozin-a new chance for patients with chronic heart failure. Pharmaceuticals, 15(1), 47, https:\/\/doi.org\/10.3390\/ph15010047.","DOI":"10.3390\/ph15010047"},{"issue":"3","key":"1164_CR104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","volume":"31","author":"J Refardt","year":"2020","unstructured":"Refardt, J., et al. (2020). A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. Journal of the American Society of Nephrology, 31(3), 615\u2013624.","journal-title":"Journal of the American Society of Nephrology"},{"key":"1164_CR105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","volume":"33","author":"S Feske","year":"2015","unstructured":"Feske, S., Wulff, H., & Skolnik, E. Y. (2015). Ion channels in innate and adaptive immunity. Annual Review of Immunology, 33, 291\u2013353.","journal-title":"Annual Review of Immunology"},{"issue":"3","key":"1164_CR106","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0165-0173(91)90011-V","volume":"16","author":"GJ Lees","year":"1991","unstructured":"Lees, G. J. (1991). Inhibition of sodium-potassium-ATPase: a potentially ubiquitous mechanism contributing to central nervous system neuropathology. Brain Research Reviews, 16(3), 283\u2013300.","journal-title":"Brain Research Reviews"},{"issue":"4","key":"1164_CR107","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0306-4522(01)00385-2","volume":"107","author":"S Li","year":"2001","unstructured":"Li, S., & Stys, P. K. (2001). Na(+)-K(+)-ATPase inhibition and depolarization induce glutamate release via reverse Na(+)-dependent transport in spinal cord white matter. Neuroscience, 107(4), 675\u2013683.","journal-title":"Neuroscience"},{"issue":"2","key":"1164_CR108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1566524043479220","volume":"4","author":"PK Stys","year":"2004","unstructured":"Stys, P. K. (2004). White matter injury mechanisms. Current Molecular Medicine, 4(2), 113\u2013130.","journal-title":"Current Molecular Medicine"},{"issue":"6","key":"1164_CR109","doi-asserted-by":"crossref","first-page":"L1186","DOI":"10.1152\/ajplung.00056.2021","volume":"320","author":"V Kryvenko","year":"2021","unstructured":"Kryvenko, V., & Vad\u00e1sz, I. (2021). Molecular mechanisms of Na,K-ATPase dysregulation driving alveolar epithelial barrier failure in severe COVID-19. American Journal of Physiology-Lung Cellular and Molecular Physiology, 320(6), L1186\u2013l1193.","journal-title":"American Journal of Physiology-Lung Cellular and Molecular Physiology"},{"key":"1164_CR110","doi-asserted-by":"crossref","first-page":"103316","DOI":"10.1016\/j.resp.2019.103316","volume":"273","author":"AM Kabel","year":"2020","unstructured":"Kabel, A. M., Estfanous, R. S., & Alrobaian, M. M. (2020). Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis. Respiratory Physiology and Neurobiology, 273, 103316.","journal-title":"Respiratory Physiology and Neurobiology"},{"issue":"6","key":"1164_CR111","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40620-017-0432-8","volume":"30","author":"G Garibotto","year":"2017","unstructured":"Garibotto, G., et al. (2017). Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. Journal of Nephrology, 30(6), 719\u2013727.","journal-title":"Journal of Nephrology"},{"issue":"4","key":"1164_CR112","first-page":"384","volume":"22","author":"Z Ashrafi Jigheh","year":"2019","unstructured":"Ashrafi Jigheh, Z., et al. (2019). Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iranian Journal of Basic Medical Sciences, 22(4), 384\u2013390.","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"1164_CR113","doi-asserted-by":"crossref","first-page":"204062232097483","DOI":"10.1177\/2040622320974833","volume":"11","author":"QQ Zhang","year":"2020","unstructured":"Zhang, Q. Q., et al. (2020). Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. Therapeutic Advances in Chronic Disease, 11, 2040622320974833.","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"11","key":"1164_CR114","doi-asserted-by":"crossref","first-page":"e108994","DOI":"10.1371\/journal.pone.0108994","volume":"9","author":"M Gangadharan Komala","year":"2014","unstructured":"Gangadharan Komala, M., et al. (2014). Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One, 9(11), e108994.","journal-title":"PLoS One"},{"key":"1164_CR115","doi-asserted-by":"crossref","first-page":"120633","DOI":"10.1016\/j.lfs.2022.120633","volume":"301","author":"DE Al-Wakeel","year":"2022","unstructured":"Al-Wakeel, D. E., El-Kashef, D. H., & Nader, M. A. (2022). Renoprotective effect of empagliflozin in cafeteria diet-induced insulin resistance in rats: Modulation of HMGB-1\/TLR-4\/NF-\u03baB axis. Life Sciences, 301, 120633.","journal-title":"Life Sciences"},{"key":"1164_CR116","doi-asserted-by":"publisher","unstructured":"Wang, C. Y., et al. (2020). TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology, 9(11), 369, https:\/\/doi.org\/10.3390\/biology9110369.","DOI":"10.3390\/biology9110369"},{"issue":"5","key":"1164_CR117","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4070\/kcj.2019.0296","volume":"50","author":"SG Lee","year":"2020","unstructured":"Lee, S. G., et al. (2020). Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model. Korean Circulation Journal, 50(5), 443\u2013457.","journal-title":"Korean Circulation Journal"},{"issue":"2","key":"1164_CR118","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/21655979.2021.2017652","volume":"13","author":"T Qin","year":"2022","unstructured":"Qin, T., et al. (2022). Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline. Bioengineered, 13(2), 2697\u20132709.","journal-title":"Bioengineered"},{"key":"1164_CR119","doi-asserted-by":"crossref","unstructured":"Ko, S. F., et al. (2022). Combined therapy with dapagliflozin and entresto offers an additional benefit on improving the heart function in rat after ischemia-reperfusion injury. Biomedical Journal, 46, 100546.","DOI":"10.1016\/j.bj.2022.06.002"},{"issue":"10-11","key":"1164_CR120","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s12012-022-09768-0","volume":"22","author":"MMM Refaie","year":"2022","unstructured":"Refaie, M. M. M., et al. (2022). Dapagliflozin guards against cadmium-induced cardiotoxicity via modulation of IL6\/STAT3 and TLR2\/TNF\u03b1 signaling pathways. Cardiovascular Toxicology, 22(10-11), 916\u2013928.","journal-title":"Cardiovascular Toxicology"},{"key":"1164_CR121","doi-asserted-by":"crossref","first-page":"908037","DOI":"10.3389\/fcvm.2022.908037","volume":"9","author":"X Zhan","year":"2022","unstructured":"Zhan, X., et al. (2022). Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway. Frontiers in Cardiovascular Medicine, 9, 908037.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"8","key":"1164_CR122","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/156652412802480970","volume":"12","author":"L Chen","year":"2012","unstructured":"Chen, L., Klein, T., & Leung, P. S. (2012). Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db\/db mice. Current Molecular Medicine, 12(8), 995\u20131004.","journal-title":"Current Molecular Medicine"},{"key":"1164_CR123","doi-asserted-by":"crossref","first-page":"111649","DOI":"10.1016\/j.biopha.2021.111649","volume":"139","author":"T Nozu","year":"2021","unstructured":"Nozu, T., et al. (2021). Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome. Biomedicine and Pharmacotherapy, 139, 111649.","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"10","key":"1164_CR124","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1177\/09603271211010906","volume":"40","author":"AM Kabel","year":"2021","unstructured":"Kabel, A. M., & Salama, S. A. (2021). Effect of taxifolin\/dapagliflozin combination on colistin-induced nephrotoxicity in rats. Human and Experimental Toxicology, 40(10), 1767\u20131780.","journal-title":"Human and Experimental Toxicology"},{"issue":"4","key":"1164_CR125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/jdi.13009","volume":"10","author":"Y Kimura","year":"2019","unstructured":"Kimura, Y., et al. (2019). Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. Journal of Diabetes Investigation, 10(4), 933\u2013946.","journal-title":"Journal of Diabetes Investigation"},{"key":"1164_CR126","doi-asserted-by":"crossref","first-page":"175357","DOI":"10.1016\/j.ejphar.2022.175357","volume":"936","author":"Y Gong","year":"2022","unstructured":"Gong, Y., et al. (2022). Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction. European Journal of Pharmacology, 936, 175357.","journal-title":"European Journal of Pharmacology"},{"key":"1164_CR127","doi-asserted-by":"crossref","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi, E., et al. (2022). Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages. European Journal of Pharmacology, 918, 174715.","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"1164_CR128","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan, U., et al. (2013). Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One, 8(2), e54442.","journal-title":"PLoS One"},{"issue":"Suppl 9","key":"1164_CR129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1399-5448.2007.00340.x","volume":"8","author":"HJ Dean","year":"2007","unstructured":"Dean, H. J., & Sellers, E. A. (2007). Comorbidities and microvascular complications of type 2 diabetes in children and adolescents. Pediatric Diabetes, 8(Suppl 9), 35\u201341.","journal-title":"Pediatric Diabetes"},{"issue":"9","key":"1164_CR130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic, D., Shaw, J. E., & Magliano, D. J. (2022). The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology, 18(9), 525\u2013539.","journal-title":"Nature Reviews Endocrinology"},{"issue":"4","key":"1164_CR131","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","volume":"146","author":"MN Kosiborod","year":"2022","unstructured":"Kosiborod, M. N., et al. (2022). Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation, 146(4), 279\u2013288.","journal-title":"Circulation"},{"issue":"3","key":"1164_CR132","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","volume":"145","author":"J Butler","year":"2022","unstructured":"Butler, J., et al. (2022). Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation, 145(3), 184\u2013193.","journal-title":"Circulation"},{"issue":"2","key":"1164_CR133","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod, M. N., et al. (2020). Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), 90\u201399.","journal-title":"Circulation"},{"key":"1164_CR134","first-page":"8867875","volume":"2020","author":"W Sha","year":"2020","unstructured":"Sha, W., et al. (2020). The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. Journal of Diabetes Research, 2020, 8867875.","journal-title":"Journal of Diabetes Research"},{"issue":"8","key":"1164_CR135","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji, K., et al. (2018). Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. International Journal of Cancer, 142(8), 1712\u20131722.","journal-title":"International Journal of Cancer"},{"issue":"Supplement_1","key":"1164_CR136","first-page":"gfz103","volume":"34","author":"Q Cheng","year":"2019","unstructured":"Cheng, Q., et al. (2019). SP434 renal tissue proteomics changes of the early tubulointerstitial injury in diabetic rats and the protective effects of sulodexide via toll-like receptor 2\/4 pathways activation. Nephrology Dialysis Transplantation, 34(Supplement_1), gfz103 SP434.","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"12","key":"1164_CR137","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","volume":"391","author":"NAT Abbas","year":"2018","unstructured":"Abbas, N. A. T., El Salem, A., & Awad, M. M. (2018). Empagliflozin, SGLT(2) inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, 391(12), 1347\u20131360.","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-023-01164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-023-01164-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-023-01164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T14:52:24Z","timestamp":1698418344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-023-01164-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":137,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1007\/s12013-023-01164-x","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"6 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}